Zhang Yang, Geng Liying, Talmon Geoffrey, Wang Jing
From the Eppley Institute for Research in Cancer and Allied Diseases, Department of Genetics, Cell Biology, and Anatomy.
From the Eppley Institute for Research in Cancer and Allied Diseases.
J Biol Chem. 2015 Mar 6;290(10):6215-25. doi: 10.1074/jbc.M114.620252. Epub 2015 Jan 23.
Development of drug resistance is one of the major causes of colorectal cancer recurrence, yet mechanistic understanding and therapeutic options remain limited. Here, we show that expression of microRNA (miR)-520g is correlated with drug resistance of colon cancer cells. Ectopic expression of miR-520g conferred resistance to 5-fluorouracil (5-FU)- or oxaliplatin-induced apoptosis in vitro and reduced the effectiveness of 5-FU in the inhibition of tumor growth in a mouse xenograft model in vivo. Further studies indicated that miR-520g mediated drug resistance through down-regulation of p21 expression. Moreover, p53 suppressed miR-520g expression, and deletion of p53 up-regulated miR-520g expression. Inhibition of miR-520g in p53(-/-) cells increased their sensitivity to 5-FU treatment. Importantly, studies of patient samples indicated that expression of miR-520g correlated with chemoresistance in colorectal cancer. These findings indicate that the p53/miR-520g/p21 signaling axis plays an important role in the response of colorectal cancer to chemotherapy. A major implication of our studies is that inhibition of miR-520g or restoration of p21 expression may have considerable therapeutic potential to overcome drug resistance in colorectal cancer patients, especially in those with mutant p53.
耐药性的产生是结直肠癌复发的主要原因之一,然而对其机制的了解和治疗选择仍然有限。在此,我们表明微小RNA(miR)-520g的表达与结肠癌细胞的耐药性相关。miR-520g的异位表达赋予了体外对5-氟尿嘧啶(5-FU)或奥沙利铂诱导的细胞凋亡的抗性,并降低了5-FU在体内小鼠异种移植模型中抑制肿瘤生长的有效性。进一步的研究表明,miR-520g通过下调p21的表达介导耐药性。此外,p53抑制miR-520g的表达,而p53的缺失上调miR-520g的表达。在p53基因敲除的细胞中抑制miR-520g可增加它们对5-FU治疗的敏感性。重要的是,对患者样本的研究表明,miR-520g的表达与结直肠癌的化疗耐药性相关。这些发现表明p53/miR-520g/p21信号轴在结直肠癌对化疗的反应中起重要作用。我们研究的一个主要意义在于,抑制miR-520g或恢复p21的表达可能具有相当大的治疗潜力,以克服结直肠癌患者尤其是那些p53突变患者的耐药性。